Valuation: Accretion Pharmaceuticals Limited

Market Cap 2.34B 24.47M 21.32M 20.17M 18.33M 34.24M 34.41M 240M 92.91M 1.19B 91.94M 89.89M 3.81B P/E 2025 *
-
P/E 2026 7.04x
Enterprise Value 2.43B 25.34M 22.07M 20.89M 18.98M 35.46M 35.63M 249M 96.2M 1.23B 95.19M 93.07M 3.95B EV / Sales 2025 *
-
EV / Sales 2026 0.88x
Free-Float
99%
Yield 2025 *
-
Yield 2026 -
1 day-0.40%
1 week-2.33%
Current month+1.45%
1 month+5.00%
3 months+39.07%
6 months+227.87%
Current year+139.04%
1 week 204.05
Extreme 204.05
219
1 month 190
Extreme 190
219
Current year 62
Extreme 62
219
1 year 53.8
Extreme 53.8
219
3 years 53.8
Extreme 53.8
219
5 years 53.8
Extreme 53.8
219
10 years 53.8
Extreme 53.8
219
Manager TitleAgeSince
Chief Executive Officer 38 2024-07-08
Director of Finance/CFO 40 2023-11-28
Compliance Officer - 2025-08-31
Director TitleAgeSince
Director/Board Member 39 2023-11-28
Chairman 40 2023-11-28
Director/Board Member 38 2023-11-19
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%-2.33%+234.13% - 24.47M
+1.28%+2.62%+51.61%+100.19% 1,027B
+1.10%+1.45%+52.49%+67.37% 651B
+0.58%+3.54%+19.57%+73.56% 467B
+0.55%+5.55%+38.93%+40.84% 350B
+0.40%+3.96%+20.46%+26.58% 268B
+0.59%+6.83%+11.20%+16.59% 257B
+0.91%-0.70%+38.25%+45.67% 205B
+0.32%+1.41%-28.57%-56.90% 190B
+2.17%+4.20%+34.41%+99.41% 187B
Average +0.37%+2.28%+47.25%+45.92% 360.21B
Weighted average by Cap. -0.03%+2.62%+35.31%+62.18%

Financials

2025 2026
Net sales 574M 5.99M 5.22M 4.94M 4.49M 8.38M 8.42M 58.82M 22.75M 292M 22.51M 22M 933M 896M 9.36M 8.15M 7.71M 7.01M 13.09M 13.16M 91.89M 35.53M 455M 35.16M 34.37M 1.46B
Net income 67.94M 709K 618K 585K 531K 993K 997K 6.96M 2.69M 34.53M 2.66M 2.61M 111M 96.68M 1.01M 879K 832K 756K 1.41M 1.42M 9.91M 3.83M 49.13M 3.79M 3.71M 157M
Net Debt 141M 1.47M 1.28M 1.21M 1.1M 2.05M 2.06M 14.41M 5.57M 71.42M 5.51M 5.39M 229M 83.01M 867K 755K 714K 649K 1.21M 1.22M 8.51M 3.29M 42.18M 3.26M 3.18M 135M
Logo Accretion Pharmaceuticals Limited
Accretion Pharmaceuticals Limited is an India-based company. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.
Employees
132
Date Price Change Volume
26-09-18 210.00 -0.40% 2,400
26-09-17 ₹210.85 +0.98% 38,400
26-09-16 ₹208.80 -4.66% 19,200
26-09-15 ₹219.00 +1.86% 8,400
26-09-11 ₹215.00 +2.38% 13,200
  1. Stock Market
  2. Stocks
  3. ACCPL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!